Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)

Press Release / Mar. 3, 2017

The company will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.

Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

Press Release / Feb. 21, 2017

The conpany announced today a collaboration with Massachusetts General Hospital (MGH) to conduct a proof of concept study evaluating the potential benefit of the Company’s Liquid Alpha-1 Antitrypsin (AAT) on liver preservation.

Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors

Press Release / Feb. 8, 2017

Kamada announced today the appointment of Gwen A. Melincoff to the Company’s Board of Directors.

Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016

Press Release / Feb. 6, 2017

Total revenues for 2016 were $77.5 million, an 11% increase over 2015. Full year 2016 Proprietary Product revenues up over 30%. Re-affirms revenue guidance of $100 million for 2017. Conference Call Today (Feb. 6) at 8:30am Eastern Time.

Kamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6

Press Release / Feb. 1, 2017

Link to webcast

Kamada management will host an investment community conference call on Monday,
February 6 at 8:30 a.m. Eastern time to discuss these results and answer questions.

Kamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on Alpha-1 Antitrypsin IV for Treatment of Acute Graft-Versus-Host Disease

Press Release / Jan. 23, 2017

Kamada announced today the positive Scientific Advice response from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) focused on the Company’s development program in Europe for Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (aGvHD) with lower gastrointestinal involvement. 

Kamada Announces Collaboration Agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin

Press Release / Nov. 15, 2016

The conpany announced today that it has signed a collaboration agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, for the development of an efficient and robust eukaryotic expression system for recombinant human Alpha 1 Antitrypsin (rhAAT).  The goal of this development work is to maximize protein yields and functionality.  

Kamada Reports Financial Results for the Third Quarter and Nine Months of 2016

Press Release / Nov. 10, 2016

The company announced financial results for the third quarter and nine months of 2016. Conference call will be held at Nov.10th, 8:30am Eastern Time

Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment

Press Release / Nov. 7, 2016

Kedrion Biopharma, and Kamada Ltd. (NASDAQ and TASE: KMDA) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a human anti-rabies immunoglobulin (IgG) therapy

Kamada Announces Plan for Phase 2/3 Clinical Trial with Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease

Press Release / Nov. 2, 2016
Kamada announced the clinical plan for the initiation of a Phase 2/3 clinical trial in the United States of its Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD), in collaboration with Shire plc.
out of 101 items.